202 related articles for article (PubMed ID: 38196540)
1. Durable response to first-line PARP inhibition in
Smith JT; Sama S; Florou V; Nevala-Plagemann C; Garrido-Laguna I
J Gastrointest Oncol; 2023 Dec; 14(6):2637-2643. PubMed ID: 38196540
[TBL] [Abstract][Full Text] [Related]
2. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
3. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
4. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
5. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Faraoni I; Graziani G
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518089
[TBL] [Abstract][Full Text] [Related]
6. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
7. Maintained complete response to talazoparib in a
Albarrán V; Chamorro J; Pozas J; San Román M; Rosero DI; Saavedra C; Gion M; Cortés A; Escalera E; Guerra E; López Miranda E; Fernández Abad M; Martínez Jañez N
Front Oncol; 2023; 13():1158981. PubMed ID: 37213307
[TBL] [Abstract][Full Text] [Related]
8. Talazoparib to treat BRCA-positive breast cancer.
Guney Eskiler G
Drugs Today (Barc); 2019 Jul; 55(7):459-467. PubMed ID: 31347614
[TBL] [Abstract][Full Text] [Related]
9. An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Cortesi L; Rugo HS; Jackisch C
Target Oncol; 2021 May; 16(3):255-282. PubMed ID: 33710534
[TBL] [Abstract][Full Text] [Related]
10. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
Zhang D; Baldwin P; Leal AS; Carapellucci S; Sridhar S; Liby KT
Theranostics; 2019; 9(21):6224-6238. PubMed ID: 31534547
[TBL] [Abstract][Full Text] [Related]
11. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
12. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Sulai NH; Tan AR
Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
[TBL] [Abstract][Full Text] [Related]
13. Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
Barchiesi G; Roberto M; Verrico M; Vici P; Tomao S; Tomao F
Front Oncol; 2021; 11():769280. PubMed ID: 34900718
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Konecny GE; Kristeleit RS
Br J Cancer; 2016 Nov; 115(10):1157-1173. PubMed ID: 27736844
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.
Zhou T; Mahn R; Möhring C; Sadeghlar F; Meyer C; Toma M; Kreppel B; Essler M; Glowka T; Matthaei H; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
Front Oncol; 2022; 12():933943. PubMed ID: 35957899
[TBL] [Abstract][Full Text] [Related]
16. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
17. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
18. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E; Selle F; Scambia G; Asselain B; Marmé F; Lindemann K; Colombo N; Mądry R; Glasspool R; Vergote I; Korach J; Lheureux S; Dubot C; Oaknin A; Zamagni C; Heitz F; Gladieff L; Rubio-Pérez MJ; Scollo P; Blakeley C; Shaw B; Ray-Coquard I; Redondo A;
Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734
[TBL] [Abstract][Full Text] [Related]
19. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
[No Abstract] [Full Text] [Related]
20. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
